Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials

IMPORTANCE: Psoriasis is a chronic disease requiring long-term management; understanding the long-term safety profiles of psoriasis treatments, such as bimekizumab, is important. OBJECTIVE: To evaluate the 2-year safety profile of bimekizumab in patients with moderate to severe plaque psoriasis. DES...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Kenneth B., Langley, Richard G., Warren, Richard B., Okubo, Yukari, Stein Gold, Linda, Merola, Joseph F., Peterson, Luke, Wixted, Krista, Cross, Nancy, Deherder, Delphine, Thaçi, Diamant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096693/
https://www.ncbi.nlm.nih.gov/pubmed/35544084
http://dx.doi.org/10.1001/jamadermatol.2022.1185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096693/
https://www.ncbi.nlm.nih.gov/pubmed/35544084
http://dx.doi.org/10.1001/jamadermatol.2022.1185

Ejemplares similares